Results 141 to 150 of about 3,791 (213)

Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate

Endocrine-Related Cancer, 2022
177Lu-Dotatate is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few prognostic markers are available to stratify progression-free survival (PFS) of patients who received 177Lu-Dotatate. Clinicopathological data including baseline circulating biomarkers of patients with advanced NET who received 177Lu-Dotatate were ...
Luohai Chen, Gopinath Gnanasegaran, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin, Shaunak Navalkissoor   +5 more
openaire   +2 more sources

Liver Steatosis Secondary to PRRT With 177Lu-DOTATATE

Clinical Nuclear Medicine, 2020
Abstract PRRT (peptide receptor radionuclide therapy) with 177Lu-DOTATATE for neuroendocrine tumor has some well-known adverse effects, concerning specially the bone marrow and kidneys. Hepatotoxicity has been rarely reported, and there are no data regarding hepatic steatosis secondary to PRRT. We reviewed upper abdomen CT and MRI and applied
Beatriz Matheos, de Lima, Juliana Ribeiro, de Carvalho, Priscilla Romano, Gaspar, Priscilla Brunelli, Pujatti, Rinaldo, Gonçalves   +4 more
openaire   +2 more sources

Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma.

Clinical Cancer Research, 2023
BACKGROUND There are no effective medical therapies for patients with meningioma who progress beyond surgical and radiotherapeutic interventions. Somatostatin receptor Type 2 (SSTR2) represents a promising treatment target in meningiomas.
Sylvia C Kurz, Elcin Zan, Christine Cordova, Andrea B Troxel, M. Barbaro, J. Silverman, M. Snuderl, D. Zagzag, D. Kondziolka, J. Golfinos, Andrew S. Chi, E. Sulman   +11 more
semanticscholar   +1 more source

Rhabdoid Papillary Meningioma Treated With 177Lu DOTATATE PRRT

Clinical Nuclear Medicine, 2015
An 18-year-old girl presented with a 3-year history of a recurrent skull base mass confirmed to be a rhabdoid papillary meningioma. The tumor was octreotide avid and metastatic to the lungs, thoracic lymph nodes, and bones, and she was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu DOTATATE.
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

Thymoma Treated With 177Lu DOTATATE Induction and Maintenance PRRT

Clinical Nuclear Medicine, 2015
A 47-year-old man presented with a recurrent thymoma World Health Organization type A of the anterior chest wall with pleural metastases after failing chemotherapy. The tumor was positive on In-octreotide, and he was referred for peptide receptor radionuclide therapy (PRRT) with Lu DOTATATE.
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma

Clinical Nuclear Medicine, 2021
Abstract A 59-year-old man with a parapharyngeal paraganglioma incidentally discovered on a cervical swelling was referred to our nuclear medicine department for a morpho-metabolic assessment. An 18F-FDG PET/CT was initially performed and found an intense hypermetabolism of the lesion and a hypermetabolism of the periadrenal brown fat evoking
Agathe, Deville, Iuliia, Pinigina, Laure, Al Mansour, Juliette, Abeillon, Jeremie, Tordo   +4 more
openaire   +2 more sources

Radiation Safety Observations Associated with 177Lu Dotatate Patients

Health Physics, 2019
Abstract Lutetium-177 dotatate, marketed under the name Lutathera®, is proving to be a valuable tool for physicians treating patients with neuroendocrine somatostatin-receptive tumors. Treatment consists of four cycles of 7.4 GBq of 177Lu dotatate infused intravenously over 30 to 40 minutes.
Kevin L, Nelson, Michael A, Sheetz
openaire   +2 more sources

Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors.

Journal of Clinical Oncology, 2022
e16212 Background: 177Lu-dotatate (LuPRRT) is effective in selected patients with metastatic neuroendocrine tumours (NETs). Most of these patients will subsequently have progressive disease with limited treatment options available. We analyzed the outcomes and toxicities of salvage LuPRRT in this study.
Hoe, Hui Jing, Wyld, David
openaire   +3 more sources

177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial

Journal of Nuclear Medicine
Visual Abstract This phase I trial aimed to assess the feasibility and toxicity of combining the poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib with 177Lu-DOTATATE in patients with somatostatin receptor–positive tumors, with the goal of
A. Hallqvist, Elva Brynjarsdóttir, Tomas Krantz, M. Sjögren, Johanna Svensson, Peter Bernhardt   +5 more
semanticscholar   +1 more source

177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial

Journal of Nuclear Medicine
Visual Abstract 177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
S. Satapathy, P. Aggarwal, A. Sood, K. Chandekar, Chandan K. Das, Rajesh Gupta, D. Khosla, Namrata Das, Rakesh Kapoor, Rajender Kumar, Harmandeep Singh, J. Shukla, Ajay Kumar, B. Mittal   +13 more
semanticscholar   +1 more source